$APRE Aprea Therapeutics, Inc. Insider Trading
Get free email notifications about insider trading in Aprea Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Aprea Therapeutics, Inc.. Insider overview, share value development, latest insider transactions and email notifications about new events in Aprea Therapeutics, Inc. for free.
CIK Number: 0001781983
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Trading Symbol: APRE
Company Address: 535 BOYLSTON STREET BOSTON 02116
Aprea Therapeutics, Inc. Latest Insider Transactions
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 11 2021 | APRE | Aprea Therapeutics ... | Korbel Gregory Alan | Chief Business Offi ... | Grant | A | 0.00 | 15,000 | 0 | 25,500 | 10.5 K to 25.5 K (+142.86 %) |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Attar Eyal C. | SVP, Chief Medical ... | Option Exercise | A | 6.00 | 143,000 | 858,000 | 143,000 | |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Attar Eyal C. | SVP, Chief Medical ... | Grant | A | 0.00 | 75,000 | 0 | 108,000 | 33 K to 108 K (+227.27 %) |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Attar Eyal C. | SVP, Chief Medical ... | Grant | A | 0.00 | 33,000 | 0 | 33,000 | 0 to 33 K |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Wessels Gregory S. | SVP, Chief Commerci ... | Option Exercise | A | 6.00 | 66,000 | 396,000 | 66,000 | |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Wessels Gregory S. | SVP, Chief Commerci ... | Grant | A | 0.00 | 16,000 | 0 | 16,000 | 0 to 16 K |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Abrahmsen Lars B. | SVP, Chief Scientif ... | Option Exercise | A | 6.00 | 82,000 | 492,000 | 82,000 | |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Abrahmsen Lars B. | SVP, Chief Scientif ... | Grant | A | 0.00 | 19,000 | 0 | 19,000 | 0 to 19 K |
Mar 01 2021 | APRE | Aprea Therapeutics ... | SCHADE CHRISTIAN S | Chairman & CEO | Option Exercise | A | 6.00 | 329,000 | 1,974,000 | 329,000 | |
Mar 01 2021 | APRE | Aprea Therapeutics ... | SCHADE CHRISTIAN S | Chairman & CEO | Grant | A | 0.00 | 88,500 | 0 | 176,660 | 88.2 K to 176.7 K (+100.39 %) |
Mar 01 2021 | APRE | Aprea Therapeutics ... | SCHADE CHRISTIAN S | Chairman & CEO | Grant | A | 0.00 | 77,000 | 0 | 77,160 | 160 to 77.2 K (+48,125.00 %) |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Coiante Scott M | SVP, Chief Financia ... | Option Exercise | A | 6.00 | 143,000 | 858,000 | 143,000 | |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Coiante Scott M | SVP, Chief Financia ... | Grant | A | 0.00 | 63,500 | 0 | 99,000 | 35.5 K to 99 K (+178.87 %) |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Coiante Scott M | SVP, Chief Financia ... | Grant | A | 0.00 | 33,000 | 0 | 35,500 | 2.5 K to 35.5 K (+1,320.00 %) |
Mar 01 2021 | APRE | Aprea Therapeutics ... | Korbel Gregory Alan | VP of Business Dev' ... | Option Exercise | A | 6.00 | 41,100 | 246,600 | 41,100 |